Sarcopenia and the Risk of Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: a Systematic Review

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2021 Feb 24

PMID 33625531

Citations 5

Authors

Yuli Guzman-Prado

Jennifer Ben Shimol

Ondrej Samson

Affiliations

Soon will be listed here.

Abstract

Background: Sarcopenia has been associated with negative clinical outcomes in cancer patients, particularly response to treatment and survival. The exponential growth in the use of immune checkpoint inhibitors (ICIs) has led to an increase in the reporting of both adverse events in general (AEs) and immune-related adverse events (irAEs), which are unintended immune-related phenomenon that take place as a result of checkpoint blockade. However, there are no systematic reviews evaluating the relationship between sarcopenia and the risk of developing AEs and irAEs in cancer patients on ICI therapies.

Methods: PubMed, MEDLINE, Embase, Cochrane and grey literature, repositories, websites Open Grey, Google Scholar, and abstracts of major international congresses were searched up to April 2020 for observational studies on sarcopenia and both AEs and irAEs in patients treated with ICIs. Study quality was assessed with The Newcastle-Ottawa quality assessment scale. PROSPERO registration number: CRD42020197178.

Results: One hundred and thirteen discrete articles were identified. Seven studies were included after evaluation of the eligibility criteria. Important sources of heterogeneity including the specific cut-points defining sarcopenia, sample size, inclusion and exclusion criteria, treatment regimen, and baseline demographics were evaluated and accounted for accordingly.

Conclusion: Most of the included studies showed an increased risk of AEs with use of ICIs in cancer patients with sarcopenia, and in the majority of these, the increase was statistically significant. Due to the small number of available studies and the expanding use of ICIs, additional research is warranted.

Citing Articles

Sarcopenia predicts immune-related adverse events due to anti-PD-1/PD-L1 therapy in patients with advanced lung cancer.

Xue D, Li N, Yang J, Men K, Li L, Jiang H Front Oncol. 2024; 14:1450020.

PMID: 39376979 PMC: 11456396. DOI: 10.3389/fonc.2024.1450020.

Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity.

Pizzutilo E, Romano R, Roazzi L, Agostara A, Oresti S, Zeppellini A Cancer Res. 2023; 83(14):2283-2296.

PMID: 37205627 PMC: 10345966. DOI: 10.1158/0008-5472.CAN-23-0161.

Inflammation as a Therapeutic Target in Cancer Cachexia.

Clamon G, Byrne M, Talbert E Cancers (Basel). 2022; 14(21).

PMID: 36358681 PMC: 9657920. DOI: 10.3390/cancers14215262.

Sarcopenia's Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.

Lee D, Kim N, Kim J, Lee J, Noh J, Lee H J Clin Med. 2021; 10(22).

PMID: 34830611 PMC: 8622936. DOI: 10.3390/jcm10225329.

Non-coding RNAs in cancer-associated cachexia: clinical implications and future perspectives.

Kottorou A, Dimitrakopoulos F, Tsezou A Transl Oncol. 2021; 14(7):101101.

PMID: 33915516 PMC: 8100623. DOI: 10.1016/j.tranon.2021.101101.

References

Quinn L . Interleukin-15: a muscle-derived cytokine regulating fat-to-lean body composition. J Anim Sci. 2007; 86(14 Suppl):E75-83. DOI: 10.2527/jas.2007-0458. View

Guzman-Prado Y, Ben Shimol J, Samson O . Body mass index and immune-related adverse events in patients on immune checkpoint inhibitor therapies: a systematic review and meta-analysis. Cancer Immunol Immunother. 2020; 70(1):89-100. PMC: 10991299. DOI: 10.1007/s00262-020-02663-z. View

Eun Y, Kim I, Sun J, Lee J, Cha H, Koh E . Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab. Sci Rep. 2019; 9(1):14039. PMC: 6773778. DOI: 10.1038/s41598-019-50574-6. View

Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P . Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. Invest New Drugs. 2017; 35(4):436-441. DOI: 10.1007/s10637-017-0464-x. View

Uojima H, Chuma M, Tanaka Y, Hidaka H, Nakazawa T, Iwabuchi S . Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. Liver Cancer. 2020; 9(2):193-206. PMC: 7206580. DOI: 10.1159/000504604. View

Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C . Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol. 2014; 33(1):90-9. DOI: 10.1200/JCO.2014.56.1894. View

Shiroyama T, Nagatomo I, Koyama S, Hirata H, Nishida S, Miyake K . Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study. Sci Rep. 2019; 9(1):2447. PMC: 6385253. DOI: 10.1038/s41598-019-39120-6. View

Lodolce J, Boone D, Chai S, Swain R, Dassopoulos T, Trettin S . IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity. 1998; 9(5):669-76. DOI: 10.1016/s1074-7613(00)80664-0. View

Ueno A, Yamaguchi K, Sudo M, Imai S . Sarcopenia as a risk factor of severe laboratory adverse events in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy. Support Care Cancer. 2020; 28(9):4249-4254. DOI: 10.1007/s00520-019-05279-x. View

10.

Tilg H, Moschen A . Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6(10):772-83. DOI: 10.1038/nri1937. View

11.

Prado C, Lieffers J, McCargar L, Reiman T, Sawyer M, Martin L . Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9(7):629-35. DOI: 10.1016/S1470-2045(08)70153-0. View

12.

Tsukagoshi M, Yokobori T, Yajima T, Maeno T, Shimizu K, Mogi A . Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer. Medicine (Baltimore). 2020; 99(7):e19059. PMC: 7035054. DOI: 10.1097/MD.0000000000019059. View

13.

Hirsch L, Bellesoeur A, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Kirchgesner J . The impact of body composition parameters on severe toxicity of nivolumab. Eur J Cancer. 2019; 124:170-177. DOI: 10.1016/j.ejca.2019.11.003. View

14.

Daly L, Power D, OReilly A, Donnellan P, Cushen S, OSullivan K . The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer. 2017; 116(3):310-317. PMC: 5294486. DOI: 10.1038/bjc.2016.431. View

15.

Lutz C, Quinn L . Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging (Albany NY). 2012; 4(8):535-46. PMC: 3461341. DOI: 10.18632/aging.100482. View

16.

Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin M, McCargar L . Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31(12):1539-47. DOI: 10.1200/JCO.2012.45.2722. View

17.

Arnaud-Coffin P, Maillet D, Gan H, Stelmes J, You B, Dalle S . A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer. 2019; 145(3):639-648. DOI: 10.1002/ijc.32132. View

18.

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015; 4:1. PMC: 4320440. DOI: 10.1186/2046-4053-4-1. View

19.

Cortellini A, Verna L, Porzio G, Bozzetti F, Palumbo P, Masciocchi C . Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report. Thorac Cancer. 2019; 10(2):347-351. PMC: 6360197. DOI: 10.1111/1759-7714.12965. View

20.

Shimizu T, Miyake M, Hori S, Ichikawa K, Omori C, Iemura Y . Clinical Impact of Sarcopenia and Inflammatory/Nutritional Markers in Patients with Unresectable Metastatic Urothelial Carcinoma Treated with Pembrolizumab. Diagnostics (Basel). 2020; 10(5). PMC: 7277993. DOI: 10.3390/diagnostics10050310. View